FIELD: bioengineering.
SUBSTANCE: aptamer connecting with chymase and inhibiting chymase activity is suggested, it contains nucleotide sequence expressed as X1GAUAGAN1N2UAAX2, where X1 and X2 identical or not identical to each other, and each means A or G, and N1 and N2 are identical or non identical to each other, and each means A, G, C, U or T; complex including aptamer and functional substance, for example, substance with affinity, substance for marking, ferment, mean of the pharmaceutical delivery, pharmaceutical; pharmaceutical or reagent containing aptamer or complex; methods of detection and cleaning of the chymase using aptamer or complex.
EFFECT: improved properties.
16 cl, 8 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APTAMER AGAINST NGF AND ITS APPLICATION | 2012 |
|
RU2633510C2 |
| MIDKINE APTAMER AND USE THEREOF | 2007 |
|
RU2460794C2 |
| APTAMER FOR FGF2 AND USE THEREOF | 2015 |
|
RU2686992C2 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| APTAMERIC THERAPEUTIC AGENTS APPLICABLE FOR TREATING COMPLEMENT-RELATED DISORDERS | 2006 |
|
RU2406507C2 |
| NUCLEIC ACID COMPOUNDS FOR BINDING GROWTH DIFFERENTIATION FACTOR 11 | 2015 |
|
RU2708170C2 |
| SDF-1 BINDING NUCLEIC ACIDS | 2007 |
|
RU2590709C2 |
| CXCL8-BINDING NUCLEIC ACIDS | 2019 |
|
RU2815444C2 |
| SDF1-BINDING NUCLEIC ACIDS AND USE THEREOF IN CANCER TREATMENT | 2011 |
|
RU2679495C2 |
| METHOD TO SEPARATE SPERMATOZOA AND APPLIED COMPOSITIONS, CONTAINING APTAMERS OR SEQUENCES OF NUCLEIC ACIDS | 2007 |
|
RU2475539C2 |
